Achieving treatment goals in low-risk, asymptomatic patients.

Abstract

Traditional risk factor assessments for coronary heart disease (CHD) often fail to take into account individual factors such as race and lipid profiles that may substantially elevate a patient's risk for CHD or a cardiovascular event. Although numerous treatment guidelines have been issued on metabolic syndrome, discrepancies among the guidelines can create confusion. Cardiac biomarkers and imaging methods have emerged to help detect and quantify subclinical atherosclerosis, but many of these are not proven as cost-effective for use in clinical practice or for routine screening. As the present case-based activity demonstrates, determining appropriate diagnostic and management strategies according to CHD risk is a process that challenges physicians to consider myriad individual patient variables.

• Authors: Keith C Ferdinand
• Journal: The Journal of the American Osteopathic Association (J Am Osteopath Assoc) Vol. 110 Issue 4 Suppl 4 Pg. S7-13 (Apr 2010) ISSN: 1945-1997 [Electronic] United States
• PMID: 20453193 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antihypertensive Agents
• Biomarkers
• Cholesterol, LDL
• Fluorobenzenes
• Hypolipidemic Agents
• Pyrimidines
• Sulfonamides
• Rosuvastatin Calcium
• C-Reactive Protein

Topics

• Black or African American
• Albuminuria (diagnosis, urine)
• Antihypertensive Agents (therapeutic use)
• Biomarkers (analysis)
• Body Mass Index
• C-Reactive Protein (analysis)
• Cholesterol, LDL (blood, drug effects)
• Coronary Disease (diagnosis, drug therapy, genetics)
• Female
• Fluorobenzenes (therapeutic use)
• Health Status Indicators
• Humans
• Hypolipidemic Agents (therapeutic use)
• Metabolic Syndrome (diagnosis, pathology)
• Middle Aged
• Obesity (diagnosis)
• Pyrimidines (therapeutic use)
• Risk Assessment
• Risk Factors
• Rosuvastatin Calcium
• Sulfonamides (therapeutic use)
• United States